Ceapro Inc.

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Ceapro Inc. trades as CRPOF on OTC. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $9.63M of revenue and -$4.71M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Ceapro Inc. can be compared against peers such as Abingdon Health Plc, American Hemp Ventures, Inc., Eiger BioPharmaceuticals, Inc., Living Cell Technologies Limited, Noxopharm Limited, Poxel S.A..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $13.31M, beta of 1.38, and return on equity of -16.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CRPOF currently shows total debt of $2.25M and beta of 1.38. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ceapro.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.